Lopinavir    (DrugBank: Lopinavir)

2 diseases
IDDisease name (Link within this page)Number of trials
93Primary biliary cholangitis [Primary biliary cirrhosis (~Mar 2017)]0
265Lipodystrophy5

93. Primary biliary cholangitis [Primary biliary cirrhosis (~Mar 2017)]    [ 230 clinical trials,   215 drugs,   (DrugBank: 51 drugs),   34 drug target genes,   107 drug target pathways]
Searched query = "Primary biliary cholangitis", "Primary biliary cirrhosis", "PBC"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: . Trials are sorted by Date_enrollment from most recent to oldest in the table.
0 / 230 trial found

265. Lipodystrophy    [ 109 clinical trials,   164 drugs,   (DrugBank: 59 drugs),   26 drug target genes,   94 drug target pathways]
Searched query = "Lipodystrophy", "Berardinelli-Seip syndrome", "Lawrence syndrome", "Barraquer-Simons syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
5 / 109 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00865007
(ClinicalTrials.gov)
December 200818/3/2009Lopinavir/r Monotherapy Versus Abacavir/Lamivudine and Lopinavir/r for Limb Fat Recovery in Persons With LipoatrophyA Phase IV-III Comparative, Randomized, Open-label Study to Evaluate the Efficacy for the Recovery of Peripheral Fat (or of the Extremities) of Lopinavir/Ritonavir in Monotherapy Versus Abacavir/Lamivudine and Lopinavir/RitonavirHIV Infection;Lipodystrophy;HIV InfectionsDrug: Monotherapy (Lopinavir/ritonavir);Drug: Monotherapy (Lopinavir/ritonavir) + ABC/3TCFundacion SEIMC-GESIDAAbbottCompleted18 YearsN/ABoth88Phase 4Spain
2NCT00192621
(ClinicalTrials.gov)
November 200412/9/2005Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy SubjectsA 3 Arm, Prospective Study to Compare the Effect of 6 Weeks Exposure to the Combination of Lopinavir (LPVr)/Combivir® (AZT/3TC) Versus Lopinavir Alone or Combivir® Alone in HIV-negative Healthy Subjects on the Development of Abnormalities of Lipid and Glucose MetabolismHIV Infections;Dyslipidemias;Glucose Metabolism Disorders;Metabolic Diseases;Lipodystrophy;Cardiovascular DiseaseDrug: Combivir (zidovudine [AZT] / lamivudine [3TC]);Drug: Kaletra (lopinavir [LPVr])Kirby InstituteSt Vincent's Hospital, Sydney;National Heart, Lung, and Blood Institute (NHLBI);Garvan Institute of Medical Research;Prince of Wales Hospital, SydneyCompleted18 YearsN/ABoth50Phase 4Australia
3NCT00139178
(ClinicalTrials.gov)
March 200430/8/2005Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir.Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir. Influence on Metabolic AbnormalitiesHIV Associated Lipodystrophy Syndrome.;HIV;Hypercholesterolemia;LipoatrophyDrug: Different HAART regimensDanish HIV Research GroupOdense University Hospital;Rigshospitalet, Denmark;Hvidovre University Hospital;Aarhus University HospitalCompleted18 YearsN/ABoth100Phase 4Denmark
4NCT00122226
(ClinicalTrials.gov)
January 200314/7/2005MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS)MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS)HIV Infections;HIV-Associated Lipodystrophy SyndromeDrug: Lopinavir/ritonavir + zidovudine + lamivudine;Drug: Lopinavir/ritonavir + nevirapineVU University Medical CenterAbbott;Boehringer IngelheimActive, not recruiting18 Years70 YearsMale50Phase 4Finland;Netherlands;Spain;United Kingdom
5NCT00028314
(ClinicalTrials.gov)
March 200220/12/2001Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV PatientsA Restrictively Randomized, Open-Label, Controlled, Pilot Study of the Effect of a Thymidine Analogue Substitution or Change to a Nucleoside-Sparing Regimen on Peripheral Fat WastingHIV Infections;Lipodystrophy;Wasting DiseaseDrug: Abacavir sulfate;Drug: Atazanavir/Ritonavir;Drug: Lopinavir/Ritonavir;Drug: NevirapineNational Institute of Allergy and Infectious Diseases (NIAID)NULLCompleted13 YearsN/ABoth150N/AUnited States